Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Willie Talbert

Internal Medicine Donaldsonville, LA Medical Doctor

NPI 1356833420 CMS profile 5377789

214 Clinic Dr, Donaldsonville, LA 70346

Open in the dashboard

General payments

$1,581

83 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Willie Talbert of Donaldsonville, LA is reported in the CMS Open Payments database as having received $1,581 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $152 1
2023 General $780 41
2022 General $580 36
2021 General $69 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Willie Talbert
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Willie Talbert were reported at $152. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Willie Talbert Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $69 $135 $37–$521 $132
2022 $580 $141 $42–$496 $149
2023 $780 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $152 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $356 29 payments
  2. Merz North America, Inc. $314 5 payments
  3. Novartis Pharmaceuticals Corporation $258 13 payments
  4. GlaxoSmithKline, LLC. $170 10 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $159 8 payments
  6. Pfizer Inc. $62 4 payments
  7. Merck Sharp & Dohme Corporation $45 2 payments
  8. Jazz Pharmaceuticals Inc. $38 1 payment
  9. AbbVie, Inc. $37 2 payments
  10. Xeris Pharmaceuticals, Inc. $35 2 payments
  11. Other $107 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,581 83 payments
Products named General payments · program years 2021–2025
  1. JARDIANCE $202 16 payments
  2. TRELEGY ELLIPTA $170 10 payments
  3. Xeomin musculoskeletal $162 4 payments
  4. EMGALITY $161 13 payments
  5. Kerendia $159 8 payments
  6. Xeomin Dermatology $152 1 payment
  7. MOUNJARO $140 12 payments
  8. LEQVIO Cardiovascular $137 7 payments
  9. ENTRESTO $137 7 payments
  10. LEQVIO Cardiology/Vascular Diseases $121 6 payments
  11. Other $790 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 155 drugs

Part D claims

14,583

Median for Internal Medicine: 777

Drug cost

$625,879

Median for Internal Medicine: $73,373

Branded share of claims

16.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 501 $107,480
Invega Sustenna Paliperidone Palmitate Brand 19 $69,620
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 55 $37,215
Ozempic Semaglutide Brand 24 $24,645
Vraylar Cariprazine Hcl Brand 35 $23,333
Caplyta Lumateperone Tosylate Brand 21 $20,561
Xarelto Rivaroxaban Brand 89 $19,307
Trulicity Dulaglutide Brand 22 $17,526
Jardiance Empagliflozin Brand 54 $15,651
Breo Ellipta Fluticasone/Vilanterol Brand 30 $13,062

The 10 drugs with the highest cost, of 155 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$12,072

Medicare's payments for the services billed

Medicare patients

111

Average age 77

Services billed

197

51 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Alzheimer's or dementia 65%
Diabetes 52%
Chronic kidney disease 50%
Heart failure 44%
COPD 42%
Arthritis 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record